Patents by Inventor Jaroslaw Maciejewski

Jaroslaw Maciejewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antitumor TET2 modulating compounds
    Patent number: 11865104
    Abstract: A method of treating cancer is described. The method includes administering a therapeutically effective amount of a TET2 activating compound or pharmaceutically acceptable salt thereof to a subject in need of treatment. The TET2 activating compounds are ?-ketoglutarate derivatives. A method of treating or preventing cancer in a subject that includes the step of analyzing a biological sample to determine if cells of the biological sample exhibit a TET2 mutation in addition to administering a TET2 activator is also described.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 9, 2024
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Jaroslaw Maciejewski, Babal K. Jha, James G. Phillips, Thomas Radivoyevitch, Yihong Guan, Anand D. Tiwari
  • Anti-aging compounds
    Patent number: 11723907
    Abstract: Anti-aging compounds identified using the lead compounds violuric acid and 1-naphthoquinone-2-monoxime are described. The compounds are redox catalysts that appear to improve the function of hematopoietic stem cells. The compounds can be used to decrease the rate of aging in a subject, or to treat or decrease the risk of developing an age-related disease or disorder.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 15, 2023
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Jaroslaw Maciejewski, Sergei Vatolin
  • ANTITUMOR TET2 MODULATING COMPOUNDS
    Publication number: 20200306221
    Abstract: A method of treating cancer is described. The method includes administering a therapeutically effective amount of a TET2 activating compound or pharmaceutically acceptable salt thereof to a subject in need of treatment. The TET2 activating compounds are a-ketoglutarate derivatives. A method of treating or preventing cancer in a subject that includes the step of analyzing a biological sample to determine if cells of the biological sample exhibit a TET2 mutation in addition to administering a TET2 activator is also described.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 1, 2020
    Inventors: Jaroslaw Maciejewski, Babal K. Jha, James G. Philips, Thomas Radivoyevitch, Yihong Guan, Anand D. Tiwari